---
title: "Novartis AG (NVS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NVS.US.md"
symbol: "NVS.US"
name: "Novartis AG"
industry: "Pharmaceuticals"
datetime: "2026-05-19T14:04:21.052Z"
locales:
  - [en](https://longbridge.com/en/quote/NVS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NVS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NVS.US.md)
---

# Novartis AG (NVS.US)

## Company Overview

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.novartis.com](https://www.novartis.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 36 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 6.31% |  |
| Net Profit YoY | 5.25% |  |
| P/B Ratio | 7.39 |  |
| Dividend Ratio | 2.07% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 284591916579.75 |  |
| Revenue | 56578000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 35.21% | A |
| Profit Margin | 23.92% | A |
| Gross Margin | 74.58% | A |
| Revenue YoY | 6.31% | C |
| Net Profit YoY | 5.25% | C |
| Total Assets YoY | 18.60% | A |
| Net Assets YoY | 1.24% | C |
| Cash Flow Margin | 141.68% | B |
| OCF YoY | 6.31% | C |
| Turnover | 0.52 | C |
| Gearing Ratio | 67.16% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Novartis AG",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "6.31%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "5.25%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "7.39",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.07%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "284591916579.75",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "56578000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "35.21%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "23.92%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "74.58%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "6.31%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "5.25%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "18.60%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.24%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "141.68%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "6.31%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.52",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "67.16%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 21.03 | 37/190 | 20.59 | 18.40 | 17.39 |
| PB | 7.39 | 167/190 | 6.39 | 6.03 | 5.68 |
| PS (TTM) | 5.03 | 98/190 | 5.05 | 4.55 | 4.31 |
| Dividend Yield | 2.07% | 19/190 | 2.15% | 2.04% | 1.87% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 17% |
| Overweight | 3 | 25% |
| Hold | 5 | 42% |
| Sell | 2 | 17% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 150.23 |
| Highest Target | 180.00 |
| Lowest Target | 123.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NVS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NVS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NVS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NVS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**